Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avibactam/ceftazidime (Primary) ; Ciprofloxacin; Cotrimoxazole; Doripenem
  • Indications Gram-negative infections; Pyelonephritis; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms RECAPTURE-1
  • Sponsors AstraZeneca

    • Most Recent Events

    • 13 Sep 2023 Results of a pooled post-hoc analysis from following clinical studies: NCT01499290, NCT01726023, NCT01644643, NCT01595438, NCT01599806 and NCT01808092 assessing clinical and microbiological outcomes and safety in patients with infections caused by beta-lactamase-producing Gram-negative pathogens published in the Journal of Antimicrobial Chemotherapy
    • 25 Oct 2020 Results assessing anti-microbial activity ceftazidime-avibactam and comparator agents against enterobacterales and pseudomonas aeruginosa with overexpression of AmpC beta-lactamase from phase 3 studies (RECLAIM , REPRISE, RECAPTURE & REPROVE), presented at the IDWeek 2020.
    • 29 Jun 2020 Results evaluating the safety of ceftazidime-avibactam in adults published in the Drug Safety

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top